(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...
Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...
U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients
ELIQUIS Dosage and Administration The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily. In patients with any two of the following characteristics (age ≥80 years, body ...
DURHAM, NC — A secondary analysis of the ARISTOTLE trial supports using the standard 5-mg twice-daily dose of apixaban (Eliquis, Bristol-Myers Squibb) in patients with atrial fibrillation (AF) who ...
In subgroup analyses, the standard apixaban dose (5 mg twice daily) was significantly associated with a higher rate of the primary outcome and a higher incidence of fatal or intracranial bleeding and ...
heart ecg arrhythmia For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...
UPDATE: With Multimedia: U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Syst
UPDATE: With Multimedia: U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk ...
Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...
Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...
MedPage Today on MSN
Watch Out for Bleeding in These Cancer Patients on Extended Anticoagulation
"Patients with cancer-associated thrombosis are both at risk of recurrent venous thromboembolism and bleeding during extended ...
Bristol-Myers Squibb Company has announced that the company is voluntarily recalling one lot of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the US to wholesalers ...
Credit: Getty Images. The recall is specific to Eliquis 5mg Tablets (60-count bottle) Lot# HN0063 with expiration date of September 2019. Bristol-Myers Squibb is recalling one lot of Eliquis (apixaban ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback